Future long-term trials of postmenopausal hormone replacement therapy – what is possible and what is the optimal protocol and regimen?

References

• MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD002978
   PubMedGoogle Scholar
• Rossouw JE, Anderson GL, Prentice RL, . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Vickers MR, MacLennan AH, Lawton B, . Main morbidities recorded in the Women's International Study of long Duration Oestrogen after Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:234–44
   PubMedGoogle Scholar
• Welton AJ, Vickers MR, Kim J, . Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190
   PubMed Web of Science ®Google Scholar
• Pal L, Hailpern SM. Cardio-deleterious implications of declining premenopausal ovarian reserve. Sexuality, Reprod Menopause 2009;17:S11–12
   Google Scholar
• Sowers M, Randolph Jr J, Jannausch M, . Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife. Implications for the timing hypothesis. Arch Intern Med 2008;168:2146–53
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol 2011;69:163–9
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Sturdee D. The end of WISDOM. Climacteric 2002;5:313–16
   PubMed Web of Science ®Google Scholar
• Harman SM, Brinton EA, Cedars M, . KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3–12
   PubMed Web of Science ®Google Scholar
• Hodis HN for the ELITE study group. http://clinicaltrials.gov/ct2/show/NCT00114517
   Google Scholar
• Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism. A systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:680–90
   PubMed Web of Science ®Google Scholar
• De Lignieres B, Basdevant A, Thomas G, . Biological effects of estradiol-17 beta in post-menopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62: 536–41
   PubMed Web of Science ®Google Scholar
• Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071–8
   PubMed Web of Science ®Google Scholar
• Alkjaersig N, Fletcher AP, de Ziegler D, Steingold KA, Meldrum DR, Judd HL. Blood coagulation in postmenopausal women given estrogen treatment: comparison of transdermal and oral administration. J Lab Clin Med 1988;111:224–8
   PubMedGoogle Scholar
• Canonico M, Oger E, Plu-Bureau G, . Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840–5
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010;8:979–86
   PubMed Web of Science ®Google Scholar
• Arana A, Varas C, Gonzalez-Perez A, Guiterrez L, Bjerrum L, Garcia Rodriguez LA. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause 2006;13:730–6
   PubMed Web of Science ®Google Scholar
• Speroff L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric 2010;13:429–32
   PubMed Web of Science ®Google Scholar
• Crook D. The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy. Br J Obstet Gynaecol 1997;104:4–14
   PubMedGoogle Scholar
• Sitruk-Ware R. New progestogens: a review of their effects in perimenopausal and postmenopausal women. Drugs Ageing 2004;21:865–83
   PubMed Web of Science ®Google Scholar
• Hermsmeyer RK, Thompson TL, Pohost GM, Kaski JC. Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? Nat Clin Pract Cardiovasc Med 2008;5:387–95
   PubMedGoogle Scholar
• Ronkin S, Northington R, Baracat E, . Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105: 1397–404
   PubMed Web of Science ®Google Scholar
• Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;20:329–35
   Google Scholar
• MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews (Online) 2004:CD002978
   PubMedGoogle Scholar
• Stram DO, Liu Y, Henderson KD, . Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause 2011;18:253–61
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women. J Gen Intern Med 2006;21:363–6
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh ME, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone therapy in younger and older women. J Gen Intern Med 2004;19:791–804
   PubMed Web of Science ®Google Scholar
• Pines A. Vasomotor symptoms and cardiovascular disease risk. Climacteric 2011;14:535–6
   PubMed Web of Science ®Google Scholar
• Lee SW, Jo HH, Kim MR, Kwon DJ, You YO, Kim JH. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet 2011 August 19. Epub ahead of print
   Web of Science ®Google Scholar
• Paine BJ, Stocks NP, MacLennan AH. Seminars may increase recruitment to randomised controlled trials: lessons learned from WISDOM. Trials 2008;9:5 doi:10,1186/1745-6215-9-5
   PubMedGoogle Scholar
• Greene JG. Measuring the symptoms dimension of quality of life: general and menopause-specific scales and their subscale structure. In Schneider HPG, ed. Hormone Replacement Therapy and Quality of Life. Lancaster: Parthenon Publishing, 2002:35–43
   Google Scholar
• O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14–22
   PubMed Web of Science ®Google Scholar
• Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium for all-cause mortality. Radiology 2003;228:826–33
   PubMed Web of Science ®Google Scholar
• Schneider HPG, MacLennan AH, Feeny D. Assessment of health-related quality of life in menopause and aging. Climacteric 2008; 11:93–107
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Henderson VW, Paine BJ, . Hormone therapy, timing of initiation, and cognition in women older than 60 years: the REMEMBER pilot study. Menopause 2006;13: 28–36
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Ann Rev Pub Health 1998;19: 55–72
   PubMed Web of Science ®Google Scholar
• Raggi P, Callister TQ, Cooil B, . Identification of patients at increased risk of first unheralded acute myocardial infarction by electron-beam computed tomography. Circulation 2000;101: 850–5
   PubMed Web of Science ®Google Scholar
• Vickers MR, Martin J, Meade TW. The Women's International Study of long-Duration Oestrogen after Menopause (WISDOM): a randomised controlled trial. BMC Women's Health 2007; 7:2
   PubMedGoogle Scholar